Disruption of HER2–HER3 dimerization is important for HER2-driven signalling and is particularly focused effectively by pertuzumab132. The beneficial success from pertuzumab trials supported a strategy of focusing on HER3, that has a vital part in HER2-mediated tumorigenesis. HER3 is unique compared with other HER members of the family as it https://www.directivepublications.org/journal-of-clinical-breast-cancer/